Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2018 Apr;66(4):680-686.
doi: 10.1097/MPG.0000000000001890.

Assuring Quality for Non-hospital-based Biologic Infusions in Pediatric Inflammatory Bowel Disease: A Clinical Report From the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition

Elaine Barfield  1 , Robbyn Sockolow  1 , Edward Hoffenberg  2 , Shehzad Saeed  3 , Sandra Kim  4 , Leah Siebold  4 , Joseph Picoraro  5 , Jonathan Moses  6 , Dana Dykes  7 , Andrew Grossman  8 , Ghassan Wahbeh  9 , K T Park  10
Affiliations
Practice Guideline

Assuring Quality for Non-hospital-based Biologic Infusions in Pediatric Inflammatory Bowel Disease: A Clinical Report From the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition

Elaine Barfield et al. J Pediatr Gastroenterol Nutr. 2018 Apr.

Abstract

The primary aim of this Clinical Report by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition is to provide formal guidance to pediatric gastroenterologists and clinicians, health systems, and insurance payers regarding home- and office-based infusions for biologic therapies in pediatric inflammatory bowel disease. Patients in North America are increasingly denied coverage by payers based on "place of service" codes at hospital-based infusion units where the treating clinicians primarily provide care. A task force with topic expertise generated 8 best practice recommendations to ensure quality of care for pediatric patients with inflammatory bowel disease receiving non-hospital-based biologic infusions. Pragmatic considerations discussed in this report include patient safety, pediatric-trained nurse availability, care coordination, patient-centeredness, shared liability, administrative support, clinical governance, and costs of care.

PubMed Disclaimer

Conflict of interest statement

Potential Conflicts of Interest: RS has received research support from Janssen and AbbVie Inc., and is a consultant for Protagonist. EH received research support from Janssen. SS is on the Speaker’s Bureau for AbbVie, Inc. SK was a consultant with Abbott (education programs and speaker) until 10/31/16. JM is on the Speaker’s bureau for AbbVie Inc. GW receives research support from AbbVie Inc and Janssen, is on the advisory board for Janssen, and is a consultant/DMC for AbbVie Inc. KTP has received research support from Janssen, Takeda, AbbVie Inc., and is supported by NIDDK094868.

Similar articles

See all similar articles

Cited by

References

    1. Benchimol E, Fortinsky K, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths A. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 2011 Jan;17(1):423–39. - PubMed
    1. Pigneur B, Seksik P, Viola S, et al. Natural history of Crohn’s disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010 Jun;16(6):953–61. - PubMed
    1. Park KT, Colletti RB, Rubin DT, Sharma BK, Thompson A, Krueger A. Health insurance paid costs and drivers of costs for patients with Crohn’s disease in the United States. Am J Gastroenterol. 2016 Jan;111(1):15–23. - PubMed
    1. Condino AA, Fidanza S, Hoffenberg EJ. A home infliximab infusion program. J Pediatr Gastroenterol Nutr. 2005 Jan;40(1):67–69. - PubMed
    1. [accessed April 4, 2017]; https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianF....

Publication types

Substances